NeoGenomics Laboratories, a leading provider of cancer-focused genetic testing services, is headquartered in the United States. Founded in 2001, the company has established itself as a key player in the oncology diagnostics industry, with major operational regions across North America and Europe.
NeoGenomics offers a comprehensive range of services, including molecular testing, pathology, and clinical trial support, distinguished by their commitment to innovation and accuracy. Their advanced testing capabilities, such as next-generation sequencing and liquid biopsy, set them apart in a competitive market.
With a strong market position, NeoGenomics has achieved notable milestones, including partnerships with prominent healthcare institutions and a growing portfolio of proprietary tests. Their dedication to improving patient outcomes through precision medicine continues to drive their success in the evolving landscape of cancer diagnostics.
-12 vs industry average
Neogenomics’s score of 20 is lower than 32% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Neogenomics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Business Services has below-average carbon intensity
Industry performance
The Business Services industry has increased its overall emissions by 24% since 2019
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Neogenomics's reported carbon emissions
In 2023, NeoGenomics, headquartered in the US, reported total emissions of approximately 4,717,000 kg CO2e. This figure comprises 536,000 kg CO2e from Scope 1 emissions and 4,181,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions, indicating potential areas for improvement in their emissions reporting. Despite the absence of specific reduction targets or initiatives, NeoGenomics is committed to addressing its carbon footprint. The company has not disclosed any science-based targets or climate pledges, which may suggest a need for enhanced climate strategies in line with industry standards. As the organisation continues to evaluate its environmental impact, it is essential for NeoGenomics to establish clear reduction goals and initiatives to align with global climate commitments.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Neogenomics’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Neogenomics yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Neogenomics
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project